BREVITY: A phase II study of brentuximab vedotin using a response adapted design in patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity
Phase of Trial: Phase II
Latest Information Update: 24 May 2019
Price : $35 *
At a glance
- Drugs Brentuximab vedotin (Primary)
- Indications Hodgkin's disease
- Focus Therapeutic Use
- Acronyms BREVITY
- 09 May 2018 Status changed from active, no longer recruiting to completed.
- 28 Nov 2015 Status changed from recruiting to active, no longer recruiting as reported by United Kingdom Clinical Research Network record.
- 01 Nov 2015 Accrual to Date is 126% according to the United Kingdom Clinical Research Network record.